Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

NCT00473577 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Neoplasms
Neoplasms

Interventions

DRUG: CRA-24781

Sponsor

Pharmacyclics LLC.